ARTICLE IN PRESS 1 2 3 4 5 6 7 8 by The Pennsylvania State University CiteSeerX Archives
Properties and physiological signiﬁcance
of fatty acid binding proteins
Norbert H. Haunerland
a and Friedrich Spener
b,*
aDepartment of Biological Sciences, Simon Fraser University, Burnaby, BC, Canada V5A 1S6
bDepartment of Biochemistry, University of Mu ¨nster, Wilhelm-Klemm-Str. 2, 48149 Mu ¨nster, Germany
pCorrespondence address: Tel.: þ49-251-83-33100; fax: þ49-251-83-32132
E-mail: spener@uni-muenster.de(F.S.)
Abbreviations
CRABP: cellular retinoic acid binding protein; CRBP: cellular retinol binding protein;
FABP: fatty acid binding protein; I-BABP: intestinal bile acid binding protein; iLBP:
intracellular lipid binding protein; ITC: isothermal titration calorimetry; PPAR:
peroxisome proliferator activated receptor; PPRE: peroxisome proliferator responsive
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1. Introduction
In 1978, Ockner et al. [1] discovered a small protein in the cytosol of certain rat tissues
that bound fatty acids and consequently named it “fatty acid binding protein” (FABP).
Since then, such FABPs have been found in many tissues of many different organisms
which include mammals, ﬁsh, birds, and insects. Some of these proteins were originally
characterized in a different context (organic anion binding protein, Z-protein) and only
later were found to be FABPs. All FABPs are members of a large multigene family now
called “intracellular lipid binding proteins” (iLBPs) with various functions in the transport
and metabolism of their ligand fatty acids and other lipophilic ligands. Many excellent
reviews have been published on different aspects of these proteins (for a recent review see
Ref. [2]), which are remarkably conserved throughout the animal kingdom. While their
roles in different cells, tissues, and organisms may vary, common features become
apparent in the context of metabolic tasks and conditions. The purpose of this review is to
summarize current knowledge about these proteins, and to provide insight into their roles
in different organisms.
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452. FABPs as members of the iLBP family
FABPs as members of the iLBP family have traditionally been named after the tissue
from which they were ﬁrst isolated. Liver-type, heart-type, and intestinal-type FABP (L-
FABP, H-FABP, I-FABP) have been the ﬁrst to be discovered [1], and later the aP2 protein
was recognized as adipocyte-type (A-) FABP [3]. With the increasing availability of ESTs
and gene array data, it has become clear that most iLBPs are not conﬁned to a single tissue.
This, however, does not necessarily mean that they are un-speciﬁcally expressed, as
tissues always contain different cell types. For example, heart tissue contains not only
cardiomyocytes, but also signiﬁcant amounts of epithelial and smooth muscle cells as well
as some adipocytes. Moreover, even deﬁned cells such as adipocytes express more than
one FABP-type [4]. This is even more apparent when FABPs expressed in non-
mammalian animals are considered: for example, the most prominent FABP-type
expressed in shark liver [5] clearly belongs to the same subfamily (see below) as H-FABP,
while the FABPs found in the livers of other ﬁsh species of chicken and are basic proteins, Q1
yet distantly related to the mammalian L-FABP [6].
In this review, the widely accepted nomenclature for FABP that is based on the tissue
occurrence will be used. The numerical classiﬁcation used by Genbank may be more
accurate, but less intuitive. In Table 1 the classical names, alternative designations found
in the literature and the GenBank designations are summarized, as is the occurrence of the
proteins in tissues of mature animals.
FABPs are expressed in vertebrate (mainly mammals, ﬁsh, birds) and invertebrate
species. Pertaining to the latter, two FABPs are expressed in the midgut of the tobacco
hornworm (Manduca sexta) [7] and believed to be involved in lipid digestion. The FABP
from the ﬂight muscle of locusts has been especially well characterized [8,9]. It is present
in high concentration and shares many characteristics with its mammalian H-FABP
counterparts. They have a high sequence homology to other insect proteins that have been
identiﬁed only at cDNA levels, namely from the fruit ﬂy (Drosophila melanogaster) [10]
and the mosquito Anopheles gambiae [11]. A protein found in the brain of the tobacco
hornworm, initially identiﬁed as a cellular retinoic acid binding protein (CRABP) [12],
belongs to the same subfamily as H-FABP as well (see below). Surprisingly, FABPs have
also been found to be prominent arthropod allergens, e.g. in the dust mites Blomia
tropicalis [13] and Acarus siro [14]. In the ﬂuke Schistosoma mansoni [15] and various
other parasitic worms [16], FABPs are considered essential for lipid absorption, since
these animals are unable to synthesize complex lipids de novo [17].
Given the wide distribution of iLBPs throughout the animal kingdom, it is apparent that
they belong to an ancient gene family. Major gene duplications gave rise to the separate
subfamilies. Multiple alignments of iLBP sequences and construction of phylogenetic
trees by the Clustal W algorithm illustrate this relationship as shown in Fig. 1. Four major
subfamilies for the mammalian proteins have been categorized based on this sequence
homology and, in addition, on ligand binding characteristics [18] (see Table 1 and Fig. 1):
(I) The intracellular retinoid binding proteins [19] can be further subdivided into the
cellular retinoic acid binding proteins (CRABP I and II) and the cellular retinol
binding proteins (CRBP I and II).
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90Table 1
Nomenclature and expression pattern for intracellular FABPs
iLBP-type Alternatives names Gene name (human) Mammalian expression Non-mammalian expression
L-FABP (liver) FABP1 Liver, intestine, kidney, lung, pancreas
I-FABP (intestinal) FABP2 Intestine
H-FABP (heart) M-FABP (muscle) FABP3 Heart, skeletal muscle, kidney, lung, mammary, Fish muscle, bird muscle, insect muscle,
MDGI placenta, testis, stomach, ovary ﬁsh ovary
A-FABP (adipocyte) ALBP FABP4 Adipose tissue Fish muscle (?)
aP2
E-FABP (epidermal) E-FABP FABP5 Skin, adipose tissue, lung, brain, heart,
KLBP skeletal muscle, testis, retina, kidney
mal1
I-BABP (intestinal) ILBP FABP6 Ileum
Gastrotropin
Brain FABP B-FABP FABP7 Brain, neurons Bird brain, retina
R-FABP
M-FABP (myelin) mP2 FABP8 Schwann cells
Myelin P2
T-FABP (testis) T-FABP FABP9 Testis
Lb-FABP (liver basic) L-FABP FABP10 Fish, chicken, iguana liver
Midgut FABP Insect midgut
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5(II) L-FABP and I-BABP (intestinal bile acid binding protein) are closely related based
on sequence homology and both stand out because of their unusual ligand binding
speciﬁcities. L-FABP, which binds a broad range of ligand molecules (acyl-CoAs,
heme, squalene, bilirubin and certain eicosanoids), is the only FABP that forms a
complex with two fatty acid molecules at the same time [20–22].
Fig. 1. Phylogenetic tree for the iLBP family. Sequences for the vertebrate and invertebrate members of the iLBP Q6
gene family were aligned with Clustal W. The tree was constructed with the neighbor joining method, using lens
lipocalin as an outgroup. For mammalian iLBPs only the human paralogs are shown. For the subfamily concept
see Sections 2 and 3 in the text.
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molecule.
(IV) This iLBP subfamily comprises the largest number of different types of FABPs,
i.e. H-, A-, E- (epidermal-type), M- (myelin-type), T- (testis-type), and B- (brain-
type) FABP. They all bind only a single fatty acid molecule.
Generally, the non-mammalian FABPs fall into one of the subfamilies as deﬁned above
and shown in Table 1 and Fig. 1, attesting to the considerable evolutionary conservation of
this protein family. Various papers have discussed the phylogenetic relationship between
the different members of the FABP family [3,23,24]. From phylogenetic analysis it is
likely that a common ancestor gene branched out into two major families more than 900
million years ago, long before the vertebrate–invertebrate divergence. Thus, subfamily II
includes not only L-FABP and I-BABP, but also the insect midgut FABPs. The FABP
from insect muscle is assembled not only with the H-FABP expressed in mammalian heart
and skeletal muscle cells, but also with the cellular retinoid binding proteins, since
subfamilies I and IV are believed to have split after the vertebrate–invertebrate
divergence [25].
3. Structure and conformation of FABPs and their ligands
The iLBPs are small proteins of 127–134 amino acids, whose expression in E. coli
made available substantial quantities of recombinant protein for biophysicists and
structural biologists to gain deeper insights into structure and binding properties of these
proteins. Thus, three-dimensional structures have been determined by X-ray crystal-
lography [22,26–30] and/or NMR [31–35] for all types of the mammalian iLBPs, with the
exception of T-FABP. In addition, the crystal [36] and solution structure [37] of the
chicken basic liver-type (Lb-) FABP are known. Of the invertebrate FABPs, the three-
dimensional structures of a midgut FABP from tobacco hornworm [38] and of the
H-FABP from desert locust [9] have been solved. From this wealth of data it has become
clear that the tertiary structure of all iLBPs is highly conserved, despite the considerable
differences in their primary structure. Sequence identities in this protein family range from
25% for some paralogous members to over 90% for some orthologs. The common
structural feature is a 10-stranded b-barrel, made of two orthogonal antiparallel 5-stranded
sheets that form the “clam”-shaped binding cavity [39]. The opening of this clam,
considered the portal domain, is framed on one side with the N-terminal helix-turn-helix
domain, a further common structural motif of all iLBPs (Fig. 2). The 10 antiparallel
strands that form the barrel is the salient feature of iLBPs within the “calycin” superfamily
of lipid binding proteins, whose other families, the avidins and lipocalins, are
characterized by 8-stranded antiparallel barrels forming the binding cavity [40].
In the binding pocket of iLBPs the deprotonated carboxyl group of the bound ligand is
generally buried inside the cavity for electrostatic interaction with one or two arginine
residues, in addition to be hydrogen bonded by a tyrosine- or serine-OH and an ordered
water molecule [27]. Nonetheless, important differences between individual iLBP-types
exist, which inﬂuence binding kinetics and afﬁnity as well as the mechanism of ligand
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225transfer [18,41]. FABP-type speciﬁc afﬁnities for fatty acids are due to different volumes
of the binding cavities and to the amino acid side chains facing one side of the fatty acid’s
hydrocarbon chain directly, and indirectly the other side via ordered water molecules. This
view is not uncontested, however (see Section 4).
A close-up inspection of protein structure and ligand conformation by crystallographic
techniques fosters the above-mentioned subfamily concept for iLBPs:
(I) The conformation of the characteristic isoprenoid tail of the retinoid ligands is
extended and the a-ionone ring located close to the helix-turn-helix domain, whereas
the functional group is always deeply immersed into the binding cavity. Here Arg111
and132 and Tyr134 directly bind all-trans retinoic acid in the case of CRABP I and II
(cellular retinoic acid binding proteins) [42] which is a scenario similar to that of
straight-chain fatty acid binding in proteins of subfamily IV. In CRBP I and II
(cellular retinol binding proteins), which bind either all-trans retinol or retinal,
Gln108 interacts with the functional group of the ligand [43,44] and in CRBP III and
IV, variants binding only retinol, Gln108 is replaced by His [45,46].
(II) Of the two fatty acids bound by L-FABP, one is coordinated in a bent conformation
electrostatically via Arg122 and an extensive hydrogen-bonding network involving
Ser124 and 39 located at the bottom of the protein cavity, which again is reminiscent
offatty acid binding in subfamilyIV. The second fatty acid inL-FABP adopts a rather
linear shape, with the acyl chain in the cavity extending down towards the center of
the other fatty acid molecule and the carboxylate sticking out of the fatty acid portal,
thus being solvent exposed and pH sensitive [22]. Interestingly, although I-BABP
contains the respective residues (Arg121, Ser123 and 38), it binds fatty acid only
weakly, instead of a bile acid molecule with high afﬁnity. Again, the bulk steroid
molecule is inside the cavity and the carboxylate group at the protein–solvent
interface [47].
Fig. 2. Three-dimensional structure of holo E-FABP (with palmitic acid) [29]. All iLBPs have the characteristic Q6
b-barrel structure, in which 10 antiparallel b-strands form the “clam”-shaped ligand binding site, framed by the
helix-turn-helix domain as part of the portal. In E-FABP, fatty acid is bound in a U-shaped conformation,
characteristic for subfamily IV iLBPs.
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270(III) The fatty acid bound by I-FABP adopts a slightly bent conformation, reverse in
direction to the second fatty acid in L-FABP, thus the carboxylate group is located
deep inside the protein cavity directly coordinated to the side-chain of Arg106 similar
to the ligands’ carboxylate bound by proteins belonging to subfamilies I and IV [26].
(IV) The FABP-types of this subfamily all bind only a single fatty acid molecule in a
U-shaped conformation. While the carboxylate group is bound electrostatically and
hydrogen bonded via Arg106 and 126 as well as Tyr128 (H-FABP numbering), the
hydrocarbon chain is located close to Phe57 (Leu60 in E-FABP) at the fatty acid
portal [27]. Several unique features in this iLBP subfamily have been reported only
recently. First, human E-FABP contains six cysteine residues, of which C120 and
C127 form a disulﬁde bridge inside the protein cavity [29]. Secondly, human
B-FABP binds oleic acid in the common U-form conformation, but very long-chain
docosahexaenoic acid (DHA) in a helical conformation [30]. It remains to be seen
whether the latter is a consequence of chain-length, or not a speciﬁc feature for
binding n 2 3 fatty acids. The three-dimensional structure of insect muscle FABP
has been solved for the apo-protein only [9]. It is remarkably similar to mammalian
H-FABP, although steric limitations seem to predict a somewhat different shape of
the ligand in the binding pocket.
4. The binding and transfer of fatty acids by FABPs
As far as we know, the obvious task of FABPs is to bind fatty acids. A total of eight
FABP-types are expressed in various mammalian tissues each carrying out distinct
metabolic tasks. Is fatty acid binding to these FABPs a mere variation of a common
structural “leitmotiv”, with little consequence for binding afﬁnities? Or do the small
structural differences in the binding sites lead to binding selectivities for distinct fatty acid
structures? It is not easy to decide which view is correct, and literature data on this aspect
are somewhat controversial.
The ADIFAB reagent is a covalently modiﬁed I-FABP, with a ﬂuorescent label that
changes its emission maximum upon the binding of fatty acids [48,49]. On the one hand,
data elaborated with this ADIFAB assay have been interpreted in terms of the “solubility
hypothesis”, which states in a ﬁrst approximation that the solubility of a given fatty acid in
the bulk aqueous phase drives its afﬁnity for any FABP. The binding site of I-FABP is
considered to act similar to a non-polar solvent, and hence its afﬁnity for different fatty
acids is mainly determined by the entropic contribution of the hydrophobic effect.
Recently, however, thermodynamic parameters for ligand double bonds were incorporated
into the calculation of dissociation constants to reﬂect physico-chemical properties of a
given FABP binding site, in fact, the enthalpic contribution to binding. For all FABP-types
and their ligand fatty acids tested so far, the values for Kds found with the ADIFAB
method are between 2 and 200 nM.
On the other hand, far greater variations in binding constants were found with other
methods. The earliest assays used charcoal to remove unbound fatty acid from the solution
and calculated binding constants from the ratio of charcoal- and protein-bound
radioactivity [50]. Soon charcoal was replaced by a lipophilic dextrane derivative,
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315Lipidex 1000 [51]. This material has strong afﬁnity to fatty acids at 37 8C, and can be used
to delipidate FABP. At 0 8C, however, protein-bound fatty acids were shown to remain
bound to FABP, while unbound fatty acids were adsorbed to Lipidex. Determination by
this method afforded dissociation constants between 0.2 and 0.4 mM which are now
considered too high, because of the low temperature and the time required to separate
Lipidex from FABP [18]. More reliable values can be obtained by measuring dissociation
constants without physically separating free from bound ligands, such as ﬂuorescence-
based methods like the ADIFAB assay. Another popular approach is isothermal titration
calorimetry (ITC), which measures the heat absorbed or released upon binding of the
ligand to the protein [18]. For mono- and polyunsaturated fatty acids, dissociation
constants in the 10–300 nM range have been determined, whereas remarkably larger
values were found for saturated fatty acids, for which the ADIFAB method suggests very
strong afﬁnity. The reasons for these discrepancies are not clear, but could be related to
solubility problems. A comparison is shown in Table 2, taking the example of B-FABP.
It follows from this short discussion (for more details, see Ref. [18]) that absolute
values of dissociation constants depend on the method used for their determination. Their
relative values, however, are comparable from method to method, in particular for Lipidex
and ITC data. Some of the latter can be explained on the basis of crystallographic studies
[52]. Moreover, further insights into binding can be gained by inspecting the dynamic
properties of FABPs through various NMR techniques, Fourier transform infrared
spectroscopy and recent molecular dynamics calculations [18]. These studies lead to the
following conclusions: (i) Differences in the backbone dynamics of various FABPs can be
correlated to preferences for speciﬁc fatty acids and their relative binding afﬁnities. (ii)
Table 2
Dissociation constants for human B-FABP/ligand complexes determined by the ADIFAB and ITC method
Ligand fatty acid class Kd (nM)
ADIFAB, 378C
a ITC, 308C
b
Saturated
Palmitic acid 7 7100
c
Stearic acid 2.3 13,500
c
Monounsaturated
Oleic acid 7 46.7 ^ 1.4
Polyunsaturated n 2 6
Linoleic acid 11 115 ^ 19
Arachidonic acid 18 207 ^ 19
Polyunsaturated n 2 3
Docosahexaenoic acid 13 53.4 ^ 4.1
a-Linolenic acid 21 27.5 ^ 1.3
aRef. [49].
bRef. [30].
cBy Lipidex assay and referenced to Kd ¼ 47 nM for oleic acid as obtained by ITC.
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360The apo-conformation of the protein can adapt to a particular ligand fatty acid and is thus
stabilized by reduced backbone ﬂexibility in some holo-FABPs [53], even “structured”
water molecules as part of the tertiary structure may add to this stability. (iii) In the portal
region, the backbone structures generally display an increased conformational variability.
Finding the correct answer to the questions raised at the start of this section is not easy.
Certainly, preferences for interactions of certain FABP-types with structurally deﬁned
fatty acid classes can be recognized, such as E-FABP with saturated fatty acids, I-FABP
with saturated and monounsaturated fatty acids, H-FABP with n 2 6 polyunsaturated fatty
acids, L-FABP with mono- and n 2 3 polyunsaturated fatty acids, and B-FABP with n 2 3
polyunsaturated fatty acids. This would have functional implications. A tenet to this
statement is that all binding data published originate from in vitro assays that may not
reﬂect the complexity seen within a cell in vivo. According to Weisiger [52], “free”
unbound fatty acids in the aqueous cellular compartments originate from their spontaneous
membrane-to-membrane transfer that is very slow and depends on the mean diffusional
excursion (dm) of a fatty acid from the membrane. The bulk of the “free” fatty acid
molecules in the cell, however, is bound to membranes and to intracellular binding
proteins, particularly FABPs. When intracellular transfer of fatty acids beyond dm is
needed, certain FABPs act as “membrane-inactive” binding proteins, and catalyze
the diffusional transfer step by increasing fatty acid concentration in the soluble
( ¼ diffusible) pool; others act as “membrane-active” binding proteins that catalyze fatty
acid dissociation from donor membranes and rebinding to acceptor membranes through
FABP-membrane collisions. This intriguing concept received convincing support by
elegant studies at the molecular level, which demonstrated that L-FABP and CRABP II
belong to the membrane-inactive, non-collisional group, while all other FAPB-types
investigated are membrane active and catalyze collisional transfer [54].
This collisional transfer of fatty acids from the FABP to zwitterionic and anionic
membranes relies on interactions with positively charged amino acid residues in the helix-
turn-helix motif and in turns belonging to the portal domain of respective FABPs [55–57].
Thus, modulation of fatty acid transfer rates in either direction depends on electrostatic
interactions of the protein with membrane lipid or protein; additional hydrophobic
interactions appear to be at work as well. If this concept is true, why does a cell need
membrane-inactive FABP, such as L-FABP at all? It has been proposed that membrane-
active FABPs would lose diffusional mobility and thus ability to catalyze efﬁcient fatty
acid transfer in cells densely packed with membranes that require efﬁcient fatty acid
transfer between membranes over some distance. Hepatocytes and enterocytes are such
cell types, and both express L-FABP [58].
5. Metabolic actions of FABPs
In contrast to the very detailed knowledge of the structure and binding characteristics of
FABPs, much less is known about their biological functions. The fact that they bind fatty
acids suggests that these proteins participate in various aspects of lipid transport and
metabolism. Many studies have demonstrated that FABPs modulate metabolic reactions in
vitro, but this does not imply that similar effects occur in living cells. Given the poor
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405solubility offatty acids in water, one can expect, for example, that the presence of FABP in
a buffer increases the availability of fatty acid to enzymes, thus leading to increased
metabolic rates in vitro. FABPs are believed to serve the following cellular tasks:
. uptake of fatty acids into the cell;
. formation of cytosolic pool for fatty acids to be rapidly utilized and, concomitantly, to
avoid detergent effects on cellular proteins and structures;
. targeting of fatty acids to speciﬁc metabolic pathways and modulation of enzymatic
activities;
. involvement in fatty acid signaling and gene regulation;
. affecting cellular growth and differentiation;
For the ﬁrst three tasks indirect evidences are available and will be generally addressed
ﬁrst in this section, followed by a detailed account of the speciﬁc FABP-types. The other
two tasks will be dealt with in Sections 7 and 8.
Uptake of fatty acids into the cell. The various mechanisms and accompanying
phenomena offatty acid uptake are being dealt with in more detail in Chapters 2, 4, 5, and
6 of this book. In these processes FABPs would be at the receiving end in the cytosol. But
the need for such cellular proteins in mediating fatty acid uptake, however, remains
controversial [59]. General experimental approaches have been transfection of
immortalized cultured cells with a certain FABP and determination of fatty acid uptake
either by radioactivity or ﬂuorescence. Thus, L-FABP enhanced initial uptake of oleic acid
into L-cell ﬁbroblasts [60] as did A-FABP in transfected CHO-cells, but not a non-binding
mutant [61]. When endogenous L-FABP concentrations were decreased by transfecting
HepG2 cells with antisense L-FABP cDNA, fatty acid uptake decreased accordingly [62].
On the other hand, expression of L-FABP mRNA in oocytes of Xenopus laevis had no
effect on fatty acid uptake [63] as had the transfection of L6 myoblast with A- and
H-FABP [64]. By the same token transfection with I-FABP cDNA of rat hBRIE 380 cells,
murine L-cell ﬁbroblasts, and human Caco-2 cells did not change the uptake kinetics of
fatty acids [65–68]. The effect of FABP on fatty acid uptake obviously differs with respect
to FABP-type and/or cell-type. Reasons can be the unknown coupling of the uptake
process to cellular utilization of the fatty acid incorporated and, of course, the unknown
proportions of the mechanisms contributing to the translocation of the fatty acid through
the membrane.
Cytosolic pool for fatty acids. Due to the amphipathic nature of fatty acids, their
accumulation in large quantities would result in the formation of micelles in the cytosol
and damage to cellular membrane structures. FABP may protect against such damage,
especially in cells that encounter large fatty acid ﬂuxes. The protein may also modulate the
regulatory effects of fatty acids on enzymes or on nuclear transcription factors.
Cytosolic fatty acid transport and targeting. Given the poor solubility of fatty acids in
aqueous media, protein-mediated transport offatty acids may be necessary to achieve high
ﬂuxes of fatty acids within cells. Indeed, tissues that metabolize large amounts of fatty
acids, such as muscle of adipose tissue, have a high FABP content. FABP increases the
total concentration of fatty acids in the cytosol, and it may transport fatty acids more
rapidly through the aqueous phase (see Section 4). The proteins may also deliver fatty
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450acids to speciﬁc intracellular compartments or enzymes, for example, to mitochondria
for b-oxidation, or to acyl-CoA synthetases for esteriﬁcation and subsequent storage
as triglycerides.
It is difﬁcult to conclusively determine how a particular FABP functions in a living cell,
especially since many cells express more than one member of the FABP gene family.
However, functional conclusions can be drawn from metabolic differences in cells, tissues,
and animals with different FABP content. At the cellular level, such differences can be
induced through the transfection of cell lines with various FABPs. FABPlevels can also be
modiﬁed through experimental conditions, such as diet, hormones, or exercise. More
recently, dramatic progress with respect to functional aspects has come from gene
disruption studies. Knock-out mice for L-FABP, H-FABP, I-FABP, A-FABP, and E-
FABP have shed light at the different functions of these proteins, but also revealed that
other members of the gene family may compensate at least partly for the loss of one
particular FABP. Other cues were obtained from comparing FABP orthologs in different
animals. This approach is especially useful for animals that have adapted to extreme rates
of lipid metabolism. In assessing the potential functions of FABPs, it is important to
distinguish between the individual members of this gene family, and to consider the
metabolic functions of the tissues in which they are expressed. Depending on the tissue,
fatty acids need to be directed to different compartments, or to different pathways. Data
from experimentally modiﬁed animals or different, specially adapted species support
functions of FABP in intracellular fatty acid trafﬁcking, but the details of underlying
mechanisms have yet to be determined.
L-FABP: Liver is a major place of biosynthesis and detoxiﬁcation, and L-FABP has
long been speculated to function in directing fatty acids or related metabolites to the
appropriate sub-cellular compartments. It may increase fatty acid acylation rates by
making fatty acid more accessible to acyl-CoA synthetase [69]. Circumstantial evidence
for a transport function was obtained from comparative studies between hepatocytes from
male and female rats. In female cells, where FABP expression is 20% higher than in males,
the fatty acid diffusion rate was markedly increased [70]. Other studies have also
demonstrated that L-FABP modulates the uptake of fatty acids. In L-FABP knock-out
mice, hepatic uptake offatty acids from the blood was reduced by 50%. This is most likely
a direct consequence of the markedly reduced fatty acid binding capacity (280%) in the
cytosol of liver cells, which do not express any other FABP. The cells, however,
maintained normal levels of non-esteriﬁed fatty acids, triglycerides, and total lipids [71].
Due to its wide range of ligands that includes xenobiotics, it has been suggested that
L-FABP may also play a role in mitogenesis [72] (see Section 8).
I-FABP: Three different members of the FABP gene family are strongly expressed
in the small intestine, albeit in different regions: cells of the proximal area of the
small intestine express mostly L-FABP, while I-FABP is found in the medial region. The
distal region expresses the intestinal bile acid binding protein (I-BABP). Since the small
intestine is involved in dietary lipid absorption, it is plausible that these proteins mediate
the uptake of lipids and their subsequent release into the bloodstream. The link between
fatty acid uptake and I-FABP content is supported by various observations in cultured
cells: Fatty acid uptake into undifferentiated stem cells was increased 1.7-fold following
transfection with I-FABP, while the reduction of I-FABP levels in cultured enterocytes by
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evidence supports a pivotal role of I-FABP in lipid absorption in vivo: A common
mutation in this FABP gene doubles the afﬁnity of I-FABP for fatty acids and results in
increased fatty acid uptake, a ﬁnding that may explain why Pima Indians, a high incidence
population group, are predisposed to type 2 diabetes [75,76]. However, targeted gene
disruption of the I-FABP gene in knock-out mice did not impair their intestinal lipid
absorption [77]. This, however, may be due to the overexpression of L-FABP in the
intestine of these animals [78]. Like in other FABP knock-out models, an alternative
FABP seems to compensate for the loss of I-FABP in the intestine of I-FABP null mice.
A-FABP: In adipocytes, free fatty acids are mostly incorporated into triacylglycerol for
subsequent storage. A-FABP is therefore thought to direct fatty acids towards
esteriﬁcation at intracellular membranes where the long-chain acyl-CoA synthetases are
located. Supporting data have been produced in experiments with primary and cultured
adipocytes (reviewed in Ref. [79]). Alternatively, a role for A-FABP may arise during
lipolysis, when free fatty acids are released from lipid droplets catalyzed by hormone
sensitive lipase. As this enzyme is subject to feedback inhibition by fatty acid, it seems
logical that rapid removal offatty acids is required for efﬁcient lipid mobilization. Indeed,
A-FABP interacts directly with hormone sensitive lipase, making it possible to sustain
rapid transport of fatty acids to the plasma membrane for export, or towards
re-esteriﬁcation at other organelles [80].
In order to study A-FABP function in vivo, a targeted disruption of its gene was
generated in mice [81]. The mice appeared to be of normal phenotype, developed normally
and were fertile. The morphology of adipocytes, and their fatty acid composition and
uptake rates were unaltered. These ﬁndings, however, cannot be taken as indication that
this FABP is not essential, as its loss greatly increased the expression of E-FABP in
adipocytes, which normally makes up only 1% of total FABP in these cells [82]. While no
changes in lipid metabolism were apparent in these animals when reared normally,
differences were seen after diet-induced obesity. In contrast to wild-type mice, A-FABP
null mice showed no increase in serum triglyceride levels, and remained sensitive to
insulin. The concentrations of free fatty acid in the adipocytes were elevated, while
lipolysis was reduced by 40% [83].
A-FABP is also expressed in macrophages which take up oxidized LDL and contribute
to the development of atherosclerosis. Atherosclerotic lesions from hypercholesterolemic,
ApoE-deﬁcient mice contained high levels of A-FABP, and it has been demonstrated that
oxidized LDL induces A-FABP expression. Double knock-out mice lacking both the
ApoE and the A-FABP gene developed smaller lesions with fewer macrophages,
indicating that macrophage A-FABP plays an important role in the formation of
atherosclerotic lesions [84–86].
E-FABP: Epidermal FABP is the most universally expressed member of this gene
family. It is the most abundant FABP in the skin. It may play a role in the maintenance of
the water-permeability barrier of the epidermis, as suggested by recent studies with knock-
out mice [87]. E-FABP null mice were of normal phenotype, and no differences were
visible in histological examinations. No differences were seen in the epidermal fatty acid
composition, but the basal trans-epidermal water loss was lower that that in wild-type
animals. When the lipid barrier was damaged by acetone treatment, the recovery period
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540required to reach the basal level was much longer than in wild-type animals [88].A
signiﬁcant increase in H-FABP expression was observed in the liver of neonatal mice,
where E-FABP is normally strongly expressed [87]. Adipocytes of E-FABP knock-out
mice showed a higher capacity for insulin-stimulated glucose transport; higher systemic
insulin sensitivity was also observed [89]. In contrast, transgenic mice overexpressing
E-FABP were less sensitive to insulin. The expression of E-FABP and A-FABP in
adipocytes is interdependent: When E-FABP is overexpressed, the levels of A-FABP are
reduced [90], while A-FABP knock-out mice reveal highly elevated levels of E-FABP
expression [82].
B-FABP: This protein is found at its highest levels in developing brain [91]. The protein
is expressed in glia cells, and its expression is regulated in response to interactions with
neurons [92,93]. Unlike most other FABPs, B-FABP does not bind palmitic acid, but
requires a longer hydrocarbon chain and a higher degrees of desaturation [94]. Its natural
ligand appears to be DHA, the very long-chain fatty acid that is essential for the
development of the nervous system. The expression of B-FABP in the brain coincides with
its requirement for DHA, and therefore B-FABP is believed to be involved in the signaling
pathways between developing neurons and glia cells [95]. B-FABP is also prominent in
neural development of avian species, for example, in the neurogenesis of glial cells in
chicken retina [96]. In contrast to the mammalian central nervous system, which is fully
developed at maturity, the brain of birds shows signiﬁcant levels of neurogenesis in the
adult stage. The presence of B-FABP in adult bird brain, and its anatomical distribution
lends credence to its role in neural migration and synaptic reorganization [97].
H-FABP: Perhaps, the clearest link between FABP and fatty acid metabolism is seen up
to date for H-FABP. This protein is the only FABP expressed in various muscle tissues, in
both vertebrates and invertebrate species [98,99]. The protein is highly conserved, even
between insects and mammals, and is found in all muscles that metabolize fatty acids. A
strong correlation exists between the fatty acid oxidation capacity of a muscle and its H-
FABP content, as illustrated in Fig. 3. Smooth muscle that depends largely on Q2
carbohydrates possesses very low levels of this FABP, while the content in red muscles
increased. With higher b-oxidation rates typical for various red muscles, equally increased
levels of H-FABP can be found [100]. Cardiac tissue, which depends mostly on lipid for
energy supply and encounters the highest b-oxidation rates of all mammalian muscles,
also has the highest FABP content (up to 5% of all cytosolic proteins). This observation
applies also to non-mammalian muscles, which need to sustain high metabolic rates for
long periods: Approximately, 9% of all cytosolic proteins are H-FABP in ﬂight muscles of
the Western sandpiper, a migratory shorebird found along the Paciﬁc coast of North and
South America; this high FABP content again reﬂects the fatty acid oxidation rates
sustained in these muscles [101]. Higher metabolic demands exist for migratory insects as
well, which retrieve energy during endurance ﬂights exclusively through b-oxidation [8].
A classical example is the ﬂight muscle of desert locust, which oxidizes almost 1 mM
of fatty acid per minute and gram tissue, as H-FABP makes up almost one-ﬁfth of all
soluble proteins.
In all these muscles, elevated levels of H-FABP expression have been observed as a
consequence of endurance training or otherwise increased fatty acid utilization. For
example, chronic electrical stimulation in rat soleus muscle led to a 30% increase in
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585H-FABP expression [100], and in vivo experiments conﬁrmed this ﬁnding: after 8 weeks
of swimming, the concentration of H-FABP in rat skeletal muscle increases by 30%,
though not in the heart [102]. Diets enriched with polyunsaturated fatty acids led to similar
effects in skeletal muscle. In spite of the already extreme H-FABP content of locust ﬂight
muscles, its further expression still can be induced, both in response to exercise and to
increased fatty acid supply alone [103]. As discussed in more detail below, H-FABP may
act as a fatty acid sensor and modulates the expression of its own gene. This would
assure that H-FABP levels are appropriate for the fatty acid transfer rates required to fuel
muscle activity.
Studies in H-FABP knock-out mice conﬁrm the importance of H-FABP for fatty acid
transport and metabolism. The absence of H-FABP did not result in phenotypical
differences, and the histology of skeletal and cardiac muscle appeared normal [104].
However, fatty acid uptake was reduced markedly in cardiac tissue (280%) and isolated
cardiomyocytes (245%). Because of the impaired fatty acid uptake, cardiac muscle
contraction in these animals relied on glucose oxidation, which can provide sufﬁcient
energy to resting animals [105]. Higher metabolic rates, however, could not be sustained.
When exercised, H-FABP null mice fatigued quickly, a ﬁnding that lends support to the
essential role of H-FABP in cardiac metabolism. Since no other FABPs are expressed in
cardiac cells, a compensation mechanism as observed in other knock-out models may not
be possible.
In contrast to vertebrates, ﬁsh appear to express both H-FABP and a protein more
similar to A-FABP in their heart and skeletal muscle [106]. This is noteworthy because
ﬁsh muscles also serve as the major lipid storage organ. The presence of A-FABP and
Fig. 3. Correlation between fatty acid oxidation capacity and FABP content in different muscles. Metabolic
rates, expressed as the oxidation of mg of palmitate per minute and gram tissue, for mammalian muscles
were taken from Ref. [100], for other muscles from Ref. [159]. FABP values for mammalian muscles
were obtained from Refs. [100,160], for locust ﬂight muscle from Ref. [8] and for sandpiper ﬂight muscle from
Ref. [161].
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630H-FABP would be consistent with distinct roles of these proteins in lipid metabolism: A-
FABP could direct fatty acids towards storage, for example, during the early stages of
migration when food intake exceeds the energy demand. H-FABP should be more
prominent during spawning when vast quantities of energy are needed.
6. Regulation of FABP gene expression
From the functional data discussed above, it is not surprising that cells in tissues with
prominent roles in fatty acid metabolism are especially rich in FABP. Moreover, FABP
levels often increase as a consequence of increased fatty acid exposure. How is this
achieved at the molecular level?
All FABPs share an identical gene structure of four conserved exons and three introns
of variable size [4,107]. This overall gene structure is of ancient origin, as it is even found
in non-mammalian species. The exon/intron boundaries are in identical positions in all
FABPs, with the only exception that the second intron has been lost in several, but not all
insect FABPs [108]. All FABP promoters contain a classical TATA box. The elements
that control the tissue-speciﬁc expression of FABP are currently only poorly understood,
but potential enhancer sequences have been characterized for several genes. These include
two HNF1a regulatory elements in the L-FABP promoter [109], a fat-speciﬁc enhancer
required for A-FABP expression in adipocytes [110], and several binding sites for
members of the POU transcription factor family that control B-FABP expression [111].A
concise promoter region that contained an atypical MEF2 binding site was shown to be
responsible for the muscle-speciﬁc expression of H-FABP [112].
Better understood is the up-regulation of various FABP genes by fatty acids. It has long
been known that the induction of FABP expression in response to lipid-rich diet [113] or
endurance training [114] is the result of increased intracellular concentrations of fatty
acids, which in turn activate nuclear transcription factors [115,116]. The best known of
such transcription factors are the subtypes of the peroxisome proliferators activated
receptor (PPAR a, b, g), so called because of their activation by xenobiotic peroxisome
proliferators in rodents [117]. Long-chain fatty acids and certain eicosanoids are
considered as their natural ligands. PPARs bind as heterodimers with the subtypes a, b, g
of the retinoid receptor RXR to direct-repeat elements (peroxisome proliferators response
elements, PPREs) in the promoter region of the genes that they regulate.
While circumstantial evidence suggests that PPARs are involved in the regulation of
various FABP genes, proof has been provided for A-FABP [118] and L-FABP [119] only.
In reporter-gene and transactivation assays Tontonoz et al. [118] have shown that the
murine A-FABP gene is regulated by the binding of PPARg2 and RXRa to a direct-repeat
element 5.2 kb upstream of the FABP gene. The expression of the rodent L-FABP gene in
the liver is under the control of PPARa bound to a PPRE around 110 bp upstream of the
transcriptional start site; interestingly, its expression in intestinal cells is controlled by
PPARb, which binds to the same response element as PPARa in the liver [120].
Several studies have demonstrated that treatment of muscle cells with the PPARa
agonist Wy14,643 resulted in elevated FABP mRNA levels, and concluded that the H-
FABP gene is also under the control of PPARa [121]. Although a direct-repeat sequence
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675reminiscent of a PPRE can be found in the distal promoter of rodent H-FABP genes, the
involvement of this element could not be demonstrated. The absence of a functional PPRE
in the human H-FABP promoter raises the possibility that PPARs may act indirectly
through cross-talk with other nuclear receptors. Alternatively, the observed induction of
gene expression by PPAR agonists could instead be a consequence of increased fatty acid
uptake into the myocyte, caused by the induction of the membrane fatty acid transporter
FAT/CD36 that is known to be controlled by PPARa [121]. While it has been proposed
that transcription factors other than PPARs may be involved in fatty acid mediated gene
control [122], such factors have not been extensively studied. To this end, insights can be
obtained from invertebrates, which do not express PPARs [123], but the ortholog of H-
FABP, which can be induced by fatty acids [103]. It is interesting to note that a different
fatty acid response element (FARE) has been identiﬁed in the promoter of the H-FABP
gene from locust muscle [108,124]. Unlike PPRE, the locust FARE is an IR-3 element, a
palindromic sequence containing two hexanucleotide half-sites (AGTGGT, ATGGGA)
separated by three nucleotides reminiscent of a steroid hormone response element.
Reporter gene constructs containing the locust FABP promoter were expressed in rat
myoblasts cells, and treatment with fatty acids resulted in a twofold increase in expression.
Deletion of the element did not affect the basal expression rate, but completely eliminated
induction by fatty acid. Nuclear proteins from rat myoblasts bound to the element in gel-
shift experiments, but additional fatty acid was required to achieve the same effect with
nuclear proteins from locust muscle [124]. Perhaps, higher concentrations of fatty acids
are required in the latter tissue, because its large FABP content may prevent full access of
a signaling fatty acid to the nuclear receptor.
The locust FARE appears to be conserved in evolution: similar elements can be found
not only within the proximity of putative FABP genes from other insects (D. melanogaster
and A. gambiae), but also in the promoters of all mammalian H-FABP genes. In the latter
case, however, the hexanucleotide half-sites (consensus sequence AGAAGA and
AGGTGA) are pointing outwards, forming an everted repeat sequence [125]. It remains
to be seen whether these elements alone are responsible for the regulation of the H-FABP
gene by a fatty acid, and which transcription factors are involved. In any case, it appears
that indeed there is more than one way by which fatty acids can control gene expression.
7. The role of FABPs in fatty acid signaling and gene transcription
The induction of A- and L-FABP mRNA expression by fatty acids and retinoids,
involving heterodimers of PPAR and RXR subtypes, is a paradigm for all genes having a
PPRE. It follows the general scheme for gene activation by lipophilic ligands that bind to
nuclear receptors of the steroid hormone receptor superfamily [126]. In A- and L-FABP
expressing cells, fatty acids thus induce their own intracellular binding proteins, a ﬁnding
that insinuates that these proteins may be the vehicles for targeted transfer of the
hydrophobic activators into the nucleus, where they become agonists of transcription
factors [126,127]. Other examples from the iLBP family include CRABP (subfamily I)
and I-BABP (subfamily II). CRABPs transport retinoic acid to the nucleus, and their genes
are under the control of retinoic acid response elements (RARE), which in turn are
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720activated by the complex of retinoic acid with RAR and RXR [128]. I-BABP is up-
regulated by its ligand as well, via the farnesoid X receptor FXR, a nuclear receptor that is
activated by bile acid [129].
The members of the iLBP family are well suited to deliver ligands into the nucleus: as
small cytosolic proteins of ,15 kDa, FABPs may readily pass nuclear pores or enter by
a speciﬁc recognition signal the nuclear compartment. Indeed, immunolabeling Q3
techniques allowed to detect nuclear localization of L-FABP in hepatocytes already in
1989 [130], of B-FABP in astrocytes [131], of A-FABP in 3T3-L1 adipocytes [132],
and of H-FABP in mammalian [133] and insect myocytes [8]. In locust muscle, the
cytosolic levels of FABP increase rapidly after adult ecdysis, and the nuclear levels were
shown to increase proportionally. Thus, it is conceivable that FABPs transfer fatty acids
to PPARs or other nuclear receptors, which in turn are activated to enhance transcription.
While the ligand exchange could be simply a matter of fatty acid afﬁnities between
binding protein and nuclear receptor, recent studies point towards direct interactions
between FABP and PPARs [134]. L-FABP and PPARa co-localize in the nucleus of
mouse hepatocytes and, as shown in vitro, the binding protein interacts via protein–
protein contacts with PPARa and g. These contacts are required for the activation of
gene expression in response to treatment of HepG2 cells with PPAR ligands, including
long-chain fatty acids. Tan et al. [135] obtained similar results using the COS cell
model: A-FABP and E-FABP interact directly with PPARg and b, respectively, and
co-expression of the binding protein and respective PPAR subtypes enhance gene
activation. Moreover, it appears translocation of the FABP into the nucleus itself is a
regulated process, with a massive import in response to ligand binding. The primary
structures of FABPs do not carry nuclear import signals; therefore, other mechanisms
must be operative. In the case of L-FABP, the negatively charged carboxylate group of
the second fatty acid molecule at the surface of the holo-protein has been considered
such a recognition signal [136,137].
While complete mechanistic details are not yet understood, it seems that FABPs act
as fatty acid sensors and mediators in the regulation of gene expression, as illustrated
in Fig. 4. This does not mean that the mechanism by protein–protein contacts is
exclusive for the ligand to become agonist. Moreover, for reasons not yet known,
conﬂicting data have been reported for the ligand dependence of these protein–protein
contacts. On the one hand, the interaction of L-FABP with PPARa or g has been
shown to be independent of the presence of ligand [134]; on the other hand, A-FABP
interacted with PPARg and E-FABP with PPARb only in the presence of ligand [138].
It is interesting to note the parallels between these FABPs and other iLBPs. It was
found that CRABP II, but not CRABP I interacts with the retinoic acid receptor
(RARa); this collisional contact leads to the transfer of all-trans retinoic acid from the
binding protein to the nuclear receptor [139]. Although the afﬁnity of 9-cis retinoic
acid to CRABP II is much lower afﬁnity than that of the trans isomer, it can be
transferred by the same collisional mechanism to RXRa [140]. Therefore, L-, A-, E-
FABP, and CRABP II appear to play complementary roles in gene regulation;
protein–protein contacts are necessary between nuclear receptors and these binding
proteins and thus can be addressed as co-activators of nuclear receptors [140].
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7658. Role of FABPs in cell growth and differentiation
Siding with the notion that FABPs target their lipophilic ligands, e.g. fatty acids or
xenobiotics, to the nucleus to affect the cell cycle, we would expect either mitogenesis or
growth arrest, the latter with or without differentiation. This modulation brought upon by
the binding protein can be seen in the light of its cytosolic sensor function in signaling
(Section 7), which may be operative only at low concentrations of the ligand [135].
However, if directed nuclear transport does not take place, the effect will be adverse in
either direction, as FABP in a concentration-dependent manner would buffer the lipophilic
ligands and prevent them from interacting with their nuclear targets.
L-FABP of subfamily II increased proliferation affected by mitogens and carcinogens
in transfected liver and hepatoma cells [72,141]. Carcinogenic peroxisome proliferators
became more potent in cells co-transfected by L-FABP, leading to higher cell proliferation
rates due to targeting [142].
In contrast, FABPs of subfamily IV reveal growth inhibitory action, for which only a
few other peptides are known such as interferons and transforming growth factor b. Thus,
loss of A-FABP was correlated with progression of human bladder transitional cell
carcinoma [143] and E-FABP, upon application to skin, reduced proliferation of
melanoma cells, while normal skin ﬁbroblasts were unaffected [144]. The gene product of
a“ mammary derived growth inhibitor-related inhibitor gene” (MRG), later identiﬁed as
B-FABP, suppressed tumor growth in a nude mouse model and breast cancer cell
proliferation after transfection with MRG [145,146]. Finally, transfection of MCF-7 cells,
a human breast cancer line, with cDNA encoding bovine H-FABP reduced cell growth, in
addition, the H-FABP producing transfectants reduced in vivo tumorigenicity [147].A t
Fig. 4. The path of signaling fatty acids to the nucleus (bold arrows). Protein–protein contacts between iLBP
(L-, A-, E-FABP, CRBP II) and the nuclear receptors are shown. The binding proteins deliver fatty acids and
retinoic acid to the nucleus, where they are transferred by collision to their respective transcription factors
(speciﬁc subtypes of PPAR and RXR). Nuclear receptor heterodimers then bind to PPRE for gene transcription.
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810present it is not clear whether or not growth inhibition is due to the FABP itself or to its
putative ligand. But it is also tempting to speculate in the case of B-FABP that the high
afﬁnity-ligand DHA (Table 2) would exert the inhibitory effect.
The background of these observations during the last 15 years was the discovery of
bovine “mammary derived growth inhibitor” (MDGI) in 1987 [Bo ¨hmer et al., JBC, 262].
It was soon recognized as a variant of H-FABP [148] and ﬁnally identiﬁed as a preparation
ofH-FABPcontaminatedwithsmallamountsofcloselyrelatedA-FABP[149].MDGIwas
a potent inhibitor of epithelial proliferation in various mammalian organ and cell cultures
[150]. MDGI, and H-FABP alone also showed anti-proliferation activity in breast cancer
cellsandH-FABPexpressionseemedtobereducedinmalignantbreasttumors[151].When
administered extracellularly, however, the anti-tumor activity of H-FABP was not due to a
bound ligand, but could be mapped to a C-terminal fragment of the protein [152]. More
details on MDGI-activities of FABPs can be found in a review published in 1998 [153].
In mammary gland organ culture, growth inhibition was associated with functional
differentiation in the presence of MDGI or H-FABP; in fact, this differentiation is
preceded by heavy expression of H-FABP in the mammary epithelial cells, which then
promotes milk protein synthesis in the differentiated cells [154]. Based on this
observation, it was argued that H-FABP acts as a differentiation factor. A-FABP as
well was assumed originally to be such a factor as it was expressed in the course of
differentiation from preadipocytes to adipocytes of both primary cells and the 3T3-L1 cell
model. Yet it was soon recognized that the fatty acids themselves (transported by E-FABP
in the preadipocyte?) are the trigger of differentiation and, as a result A-FABP and PPARg
among others are expressed. In fully differentiated adipocyte culture, removal of fatty
acids from the medium and re-supplementation decreased and replenished A-FABP
mRNA levels, respectively [155]. From today’s perspective we can ascribe to A-FABP a
carrier function in fatty acid signaling to the nucleus to interact with PPARg and a
transport function needed during the time of heavy triacylglycerol accumulation. Indeed,
tissue-speciﬁc enhancer and proximal promoter regions of the A-FABP gene interact
with adipogenic transcription factors in a time-dependent manner [156]. In line with this,
H-FABP in C2C12 cells was induced upon differentiation from the myoblast to the
myotube stage [157]. A careful follow-up study demonstrated later that E-FABP in
myoblasts is down-regulated during differentiation, while H-FABP was induced at later
stages of differentiation when energy retrieval in the cells shifts from glycolysis to
b-oxidation, indicative of a metabolic transport function of the binding protein [158].
9. Outlook
Much progress has been made in the last decade in the study of the structure and
binding behavior of the FABPs. Much of the current research activity is directed to
understand the control of their gene expression, and the interactions of FABPs with other
proteins in the cell. Undoubtedly, these studies will help to more fully understand the
pleiotropic roles of these intracellular transport proteins, especially with respect to signal
transduction, both at the molecular and the cellular level. It is the belief of the authors that
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insights into their regulatory functions.
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